Loading market dashboard
Franklin Covey Co.
FCIndustrialsNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
[url="]Ironwood Pharmaceuticals, Inc.[/url] (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living wi
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of LINZESS® (linaclotide) in pediatric patients 2 years of age and older with functional constipation (FC). LINZESS was previously approved for pediatric patients 6 years and older with FC. With thi.
As organizations race to capture the benefits of artificial intelligence, research from [url="]FranklinCovey[/url] Institute reveals a critical obstacle: most
SALT LAKE CITY--(BUSINESS WIRE)-- #AI--As organizations race to capture the benefits of artificial intelligence, research from FranklinCovey Institute reveals a critical obstacle: most employees feel they are navigating AI alone, without meaningful support or guidance. Eighty percent of individual contributors describe their manager's approach to AI as “hands-off,” which underscores a widening gap between AI's potential and how it's actually used at work. FranklinCovey's 2025 AI General Attitudes Sur.
Diploma LON: DPLM reported what management described as a “very strong” first half for the six months ended March 31, 2026, with double-digit organic growth, higher margins and upgraded full-year expectations.
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that full results of its ADVANCE OUTCOMES study are being present
TORONTO, May 05, 2026 (GLOBE NEWSWIRE) -- Firm Capital Mortgage Investment Corporation (the “Corporation”) (TSX FC, FC.DB. K, FC.DB. L and FC.DB.M) today released its financial statements for the three months ended March 31, 2026.
Franklin Covey (NYSE: FC) executives said the company's fiscal second quarter 2026 results showed continued momentum from its go-to-market changes in Enterprise North America, with invoiced amounts rising and deferred revenue building, while the Education Division delivered double-digit revenue growth. Management highlights: invoice growth and expanding deferred revenue CEO Paul Walker said the company was "pleased
As of April 2, 2026, two stocks in the industrials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Franklin Covey Co. (FC) Q2 2026 Earnings Call Transcript
Franklin Covey (FC) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of breakeven. This compares to a loss of $0.08 per share a year ago.
SALT LAKE CITY--(BUSINESS WIRE)--Franklin Covey Co. (NYSE: FC), a global leadership and organizational performance partner, gives strategy the human edge. We help clients achieve breakthrough results and transform how they execute strategy at scale. Today, the Company announced its financial results for the second quarter of fiscal 2026, which ended on February 28, 2026. Second Quarter Fiscal 2026 Financial Overview The Company's consolidated revenue for Q2 FY2026 was $59.6 million, which was f.
SALT LAKE CITY--(BUSINESS WIRE)-- #CNO--FranklinCovey Provides Customized Solutions for Healthcare Organizations to Solve Key Issues: Nurse Retention and Patient Satisfaction.
Despite the recent fundamental declines, I believe Franklin Covey remains structurally attractive with material untapped TAM despite that should prevail past recent weakness. I'll be watching for continued sales momentum as reflected in Q1, continued new logo growth generation, SG&A levels, guidance, and capital allocation (particularly share repurchases). Despite the price run-up in recent weeks, I still believe FC offers an attractive IRR.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Franklin Covey (FC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The mean of analysts' price targets for Franklin Covey (FC) points to a 99.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Franklin Covey (FC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
DRAPER, Utah--(BUSINESS WIRE)--Franklin Covey Co. (NYSE: FC), a leader in organizational performance improvement, announced today that the conference call to review the Company's second quarter 2026 financial results will take place on Wednesday, April 1, 2026, at 5:00 p.m. ET (3:00 p.m. MT). The Company's financial results are expected to be released after the close of the market on Wednesday, April 1, 2026. Interested persons may access a live webcast https://edge.media-server.com/mmc/p/qux25.
Franklin Covey (FC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Three of the portfolio's 10 equity sectors made positive contributions to calendar-year period performance: Health Care and Financials led by wide margins, followed by Information Technology. PACS Group reported stronger-than-expected fiscal 2024 and year-to-date fiscal 2025 results in November of 2025, signaling that its acquisition and operating models remained on track. FTAI shares significantly outperformed in 2025 due to robust demand for passenger flights and from strengthening its moat by acquiring a new repair facility in Rome.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Franklin Covey (FC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
